358 related articles for article (PubMed ID: 25034573)
1. Reproductive function assessment after surgery plus chemotherapy for germ cell ovarian tumors (MOGCT): novel clues deriving from the field of fertility preservation.
Ottolina J; Mangili G; Sigismondi C; Vanni VS; Viganò P; Candiani M
Gynecol Endocrinol; 2014 Nov; 30(11):778-80. PubMed ID: 25034573
[TBL] [Abstract][Full Text] [Related]
2. Long-term oncological and reproductive outcomes of fertility-sparing cytoreductive surgery in females aged 25 years and younger with malignant ovarian germ cell tumors.
Ertas IE; Taskin S; Goklu R; Bilgin M; Goc G; Yildirim Y; Ortac F
J Obstet Gynaecol Res; 2014 Mar; 40(3):797-805. PubMed ID: 24320102
[TBL] [Abstract][Full Text] [Related]
3. Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours.
Gadducci A; Lanfredini N; Tana R
Gynecol Endocrinol; 2014 Jul; 30(7):467-71. PubMed ID: 24702194
[TBL] [Abstract][Full Text] [Related]
4. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era".
Solheim O; Tropé CG; Rokkones E; Kærn J; Paulsen T; Salvesen HB; Hagen B; Vereide AB; Fosså SD
Gynecol Oncol; 2015 Feb; 136(2):224-9. PubMed ID: 25511159
[TBL] [Abstract][Full Text] [Related]
5. Young girls with malignant ovarian germ cell tumors can undergo normal menarche and menstruation after fertility-preserving surgery and adjuvant chemotherapy.
Yoo SC; Kim WY; Yoon JH; Chang SJ; Chang KH; Ryu HS
Acta Obstet Gynecol Scand; 2010; 89(1):126-30. PubMed ID: 19878051
[TBL] [Abstract][Full Text] [Related]
6. Anti-Müllerian hormone as a marker of ovarian reserve in patients with ovarian malignancies who have undergone fertility-preserving surgery and chemotherapy.
Iwase A; Sugita A; Hirokawa W; Goto M; Nakahara T; Bayasula ; Kajiyama H; Shibata K; Nagatomo Y; Kikkawa F
Gynecol Endocrinol; 2013 Apr; 29(4):357-60. PubMed ID: 23305483
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.
Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2015 Jun; 137(3):418-22. PubMed ID: 25842162
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors.
Zhang N; Chen R; Hua K; Zhang Y
J Ovarian Res; 2017 Jul; 10(1):52. PubMed ID: 28750644
[TBL] [Abstract][Full Text] [Related]
9. Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences.
Zamani N; Rezaei Poor M; Ghasemian Dizajmehr S; Alizadeh S; Modares Gilani M
BMC Womens Health; 2021 Aug; 21(1):282. PubMed ID: 34348686
[TBL] [Abstract][Full Text] [Related]
10. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases.
Low JJ; Perrin LC; Crandon AJ; Hacker NF
Cancer; 2000 Jul; 89(2):391-8. PubMed ID: 10918171
[TBL] [Abstract][Full Text] [Related]
11. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
[TBL] [Abstract][Full Text] [Related]
12. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors.
Weinberg LE; Lurain JR; Singh DK; Schink JC
Gynecol Oncol; 2011 May; 121(2):285-9. PubMed ID: 21256579
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
Yang ZJ; Wei RJ; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
[TBL] [Abstract][Full Text] [Related]
14. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary.
Talukdar S; Kumar S; Bhatla N; Mathur S; Thulkar S; Kumar L
Gynecol Oncol; 2014 Jan; 132(1):28-32. PubMed ID: 24145115
[TBL] [Abstract][Full Text] [Related]
15. [Results of fertility preserving operations in malignant ovarian tumors].
Kleine W
Zentralbl Gynakol; 1996; 118(6):317-21. PubMed ID: 8768006
[TBL] [Abstract][Full Text] [Related]
16. Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center.
Mikuš M; Benco N; Matak L; Planinić P; Ćorić M; Lovrić H; Radošević V; Puževski T; Bajt M; Vujić G
Arch Gynecol Obstet; 2020 May; 301(5):1227-1233. PubMed ID: 32253553
[TBL] [Abstract][Full Text] [Related]
17. An Analysis of Prognostic Factors in Patients with Ovarian Malignant Germ Cell Tumors Who Are Treated with Fertility-Preserving Surgery.
Yang ZJ; Liu ZC; Wei RJ; Li L
Gynecol Obstet Invest; 2016; 81(1):1-9. PubMed ID: 25967958
[TBL] [Abstract][Full Text] [Related]
18. Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
Morrison A; Nasioudis D
Gynecol Oncol; 2020 Aug; 158(2):476-483. PubMed ID: 32513565
[TBL] [Abstract][Full Text] [Related]
19. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
[TBL] [Abstract][Full Text] [Related]
20. Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.
Policiano C; Subirá J; Aguilar A; Monzó S; Iniesta I; Rubio Rubio JM
J Assist Reprod Genet; 2020 Jul; 37(7):1755-1761. PubMed ID: 32488563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
